---
document_datetime: 2023-09-21 21:56:24
document_pages: 5
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/pioglitazone-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: pioglitazone-teva-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.6734335
conversion_datetime: 2025-12-28 15:50:43.155145
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Pioglitazone Teva

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amendedon   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|--------------------------------------------|----------------------------------|-----------|
| N/0025               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) Product                                                                                                       | 04/11/2021                          |                                            | PL                               |           |
| IA/0024              | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                  | 01/02/2021                          | 21/06/2021                                 | Annex II and PL                  |           |
| WS/1791              | This was an application for a variation following a worksharing procedure according to Article 20 of Commission Regulation (EC) No 1234/2008. The RMP was updated to the RMP template rev2 as per GVP module V | 11/06/2020                          | 21/06/2021                                 | Annex II                         |           |

Medicinal Product no longer authorised

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | rev 2, and the existing additional riskminimisation measures (educational packfor the healthcare professionals containing a prescriber guide) were removed both from the RMP and their key elements from the Annex IID of the PI, in line with the originator product for pioglitazone. In addition,standard wording was reinstated for the PSUR submission requirement with a reference to the updates included in the EURD list. C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of change(s) which require to be further substantiated bynew additional data to be submitted by the MAH where significant assessment is required   | longer        | 28/11/2018 authorised   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|-------------------------|
| IAIN/0022 | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 11/12/2017 no |                         |
| IB/0021/G | This was an application for a group of variations. B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits B.II.f.1.e - Stability of FP - Change to an approved stability protocol Product                                                                                                                                                                                                                                                                                                                                   | 26/07/2017    | n/a                     |
| IA/0019   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 05/04/2017    | n/a                     |
| N/0020    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) Medicinal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 30/03/2017    | 28/11/2018              |

<div style=\"page-break-after: always\"></div>

| R/0016    | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                                     | 15/12/2016        | 17/02/2017   | authorised                       | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit- risk balance of Pioglitazone Teva in the approved indications remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------|--------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0018   | B.II.a.3.b.1 - Changes in the composition (excipients) of the finished product - Other excipients - Any minor adjustment of the quantitative composition of the finished product with respect to excipients                                                                                                                 | 02/02/2017 longer | n/a          |                                  |                                                                                                                                                                                                                                                                                     |
| IB/0017   | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                              | 10/10/2016 no     | 14/11/2016   | SmPC and PL                      |                                                                                                                                                                                                                                                                                     |
| IB/0015   | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH Product                                                        | 20/07/2016        | 14/11/2016   | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                     |
| IA/0014/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer/importer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites Medicinal | 29/06/2016        | n/a          |                                  |                                                                                                                                                                                                                                                                                     |
| IA/0013   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                               | 25/04/2016        | 14/11/2016   | Annex II and PL                  |                                                                                                                                                                                                                                                                                     |

<div style=\"page-break-after: always\"></div>

| IAIN/0012   | B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing                                                                                                                                                 | 27/11/2015    | 14/11/2016   | Annex II and PL and PL authorised   |             |
|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|--------------|-------------------------------------|-------------|
| T/0011      | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                                    | 22/12/2014    | 30/01/2015   | SmPC, Labelling                     |             |
| IB/0010     | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                 | 27/10/2014    | n/a          |                                     |             |
|             | This was an application for a group of variations. B.III.2.a.1 - Change of specification(s) of a former non EU Pharmacopoeial substance to fullycomply with the Ph. Eur. or with a national pharmacopoeia of a Member State - AS B.I.b.1.b - Change in the specification parameters and/or limits ofan AS, starting material/intermediate/reagent - Tightening of specification limits | 26/09/2014 no | n/a longer   |                                     | IAIN/0009/G |
| IB/0008     | B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation Product                                                                                                                                                                                                                                         | 19/09/2014    | n/a          |                                     |             |
| IB/0007     | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                                                                                                                          | 29/07/2014    | n/a          | SmPC, Annex II,                     |             |
| IB/0006/G   | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH Medicinal                                                              | 25/11/2013    | 16/12/2014   | Labelling and PL                    |             |

<div style=\"page-break-after: always\"></div>

|           | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                             | authorised                |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------|
| IAIN/0005 | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                           | 21/05/2013 n/a            |
| IA/0004/G | This was an application for a group of variations. A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) A.7 - Administrative change - Deletion of manufacturing sites | 10/04/2013 n/a longer     |
| IAIN/0003 | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site no                                                                                                                                                                                                    | 15/06/2012 n/a            |
| IB/0002   | B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place,except batch- release,batch control,primary and secondarypackaging,for non-sterile medicinal products Product                                                             | 14/06/2012 n/a 14/06/2012 |
| IB/0001   | B.II.b.1.e - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place,except batch- release,batch control,primary and secondarypackaging,for non-sterile medicinal products Medicinal                                                           | n/a                       |